Biogen (BUE:BIIB) Days Sales Outstanding

: 81.11 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's average Accounts Receivable for the three months ended in Dec. 2023 was ARS765,692 Mil. Biogen's Revenue for the three months ended in Dec. 2023 was ARS861,454 Mil. Hence, Biogen's Days Sales Outstanding for the three months ended in Dec. 2023 was 81.11.

The historical rank and industry rank for Biogen's Days Sales Outstanding or its related term are showing as below:

BUE:BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.81 Med: 64.02 Max: 78.66
Current: 78.66

During the past 13 years, Biogen's highest Days Sales Outstanding was 78.66. The lowest was 39.81. And the median was 64.02.

BUE:BIIB's Days Sales Outstanding is ranked worse than
57.06% of 999 companies
in the Drug Manufacturers industry
Industry Median: 71.93 vs BUE:BIIB: 78.66

Biogen's Days Sales Outstanding increased from Dec. 2022 (67.81) to Dec. 2023 (81.11).

Biogen Days Sales Outstanding Historical Data

The historical data trend for Biogen's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

51.26

56.22

63.77

59.52

57.38

Biogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															67.81	71.16	70.47	66.11	81.11

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biogen's Days Sales Outstanding falls into.

Biogen Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biogen's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (358167.45	+	758100.001)	/	2 )	/	3550651.603	*	365
=	558133.7255					/	3550651.603	*	365
=	57.38

Biogen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (773284.536	+	758100.001)	/	2 )	/	861454.301	*	365 / 4
=	765692.2685					/	861454.301	*	365 / 4
=	81.11

Biogen (BUE:BIIB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Biogen Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biogen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.